Form 4: Centessa General Counsel Executes Option, Sells Shares

Centessa Pharmaceuticals plc's General Counsel, Iqbal J Hussain, exercised stock options and sold an equivalent number of shares under a pre-arranged trading plan.

Summary

• Iqbal J Hussain, General Counsel of Centessa Pharmaceuticals plc (CNTA), engaged in a transaction on August 15, 2025.
• Hussain exercised options to acquire 6,000 Ordinary Shares at a price of $5.84 per share.
• Concurrently, 6,000 Ordinary Shares were sold at a price of $17.23 per share.
• The sale was conducted pursuant to a Rule 10b5-1 trading plan adopted by Hussain on September 14, 2024.
• Following these transactions, Hussain directly beneficially owns 105,386 Ordinary Shares.
• An additional 5,500 Ordinary Shares are indirectly beneficially owned by Hussain's spouse.
• Hussain retains 279,559 share options, which have an exercise price of $5.84 and an expiration date of February 19, 2031.
• The options' vesting schedule began on February 19, 2022, with 25% vesting immediately and the remaining 75% vesting in 36 monthly installments thereafter.

Sentiment

Score: 5

Explanation: A routine insider transaction under a 10b5-1 plan is generally neutral. It reflects personal financial planning rather than a direct signal about the company's immediate prospects. The profitability of the transaction for the insider is positive for them but doesn't inherently change the company's outlook.

Positives

• The insider's sale price of $17.23 is significantly higher than the exercise price of $5.84, indicating a profitable transaction for the General Counsel.
• The execution of the transaction under a Rule 10b5-1 plan suggests a pre-planned liquidity event rather than a reaction to new, negative information.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived by the market as a lack of confidence, though this is a common practice for personal financial management.

Future Outlook

The remaining 75% of the share options will continue to vest in 36 monthly installments on the first day of each month following February 19, 2022.

Industry Context

This transaction is a routine insider stock activity and does not provide specific insights into broader industry trends or competitive dynamics within the pharmaceutical sector.

Stakeholder Impact

• Shareholders: The sale of shares by an insider, even under a 10b5-1 plan, could be interpreted by some as a minor negative signal, though it is a common and often pre-scheduled event for liquidity and diversification.
• Employees: No direct impact.

Next Steps

• Remaining share options will continue to vest monthly.

Key Dates

Recommendation

This Form 4 reports a routine insider transaction (exercise of options and sale of shares) executed under a pre-arranged Rule 10b5-1 trading plan. Such transactions are typically for personal financial planning and diversification, and do not inherently signal a change in the company's fundamental outlook or the insider's confidence. The transaction itself does not provide new information to warrant a change in investment thesis.

Keywords

Centessa Pharmaceuticals, CNTA, Insider Trading, Form 4, Stock Options, Share Sale, Iqbal J Hussain, General Counsel, Rule 10b5-1